HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

MEDTIDE

19.920

-0.030-0.15%

Volume:100.60K

Turnover:2.00M

Market Cap:2.82B

PE:10.46

High:20.000

Open:19.600

Low:19.500

Close:19.950

52wk High:34.300

52wk Low:19.000

Shares:141.80M

HK Float Shares:141.80M

Volume Ratio:1.04

T/O Rate:0.07%

Dividend:- -

Dividend Rate:- -

EPS(LYR):1.904

ROE:10.89%

ROA:6.82%

PB:1.48

PE(LYR):10.46

PS:4.39

Loading ...

Overview Company News Filings

Precision Peptide Starts U.S. Testing of Thymosin Alpha-1 Transdermal Patch

Medtide (SEHK:3880) Stock Drifts As Margin Gains Meet Revenue Reset

Simply Wall St.

MEDTIDE Proposes Adoption of Restricted Share Unit Scheme

MEDTIDE Posts 47.4% Drop in Net Profit for Interim Results

Medtide Proposes Bylaw Changes to Allow Board Size Range of Five to Nine Directors

Medtide Proposes 10-Year RSU Incentive Scheme with 14,180,000-Share Mandate Limit

Medtide Hy Revenue Rmb234.5 Mln

THOMSON REUTERS

Medtide H1 FY26 Profit Drops 47.4% to RMB 53.68 Million; Revenue Falls 7.6% to RMB 234.52 Million

Precision Peptide Develops Needle-Free Tirzepatide Transdermal Patch in U.S

Medtide Schedules Board Meeting to Review Interim Results

Hong Kong Stock CXO Sector Rallies; Will MEDTIDE (03880) Defy the Trend or Bounce Back After Its Profit Warning?

Cpc Scientific Announces U.S. FDA Pre-License Inspection (Pli) Successfully Completed at Its Hangzhou Cgmp Manufacturing Facility for Hepcludex® API, Establishing a Proven Track Record Under the Stringent Bla Pathway

THOMSON REUTERS

Medtide Posts Steady July 2026 Share Capital; Public Float Remains Compliant

Bulletin Express

Medtide completes U.S. FDA Pre-License Inspection for Hepcludex API at Hangzhou facility

Bulletin Express

MEDTIDE (03880) Issues Profit Warning, Expects First-Half Profit to Drop Approximately 44% to 51.6% Year-on-Year

MEDTIDE's HEPCLUDEX® Active Ingredient Passes FDA Pre-License Inspection

MEDTIDE Appoints New CFO and Revamps Key Management Positions

Medtide Unit Chinese Peptide Completes US FDA Pre-license Inspection for Hepcludex API Facility

Medtide Names Ding Lijun as CFO

Medtide - Subsidiary Completes U.S. FDA Pre-License Inspection at Hangzhou Facility

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrnexa.com/stock/03880/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"03880","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"03880\",,,,,undefined,":{"symbol":"03880","market":"HK","secType":"STK","nameCN":"MEDTIDE","latestPrice":19.92,"timestamp":1789027722262,"preClose":19.95,"halted":0,"volume":100600,"delay":0,"changeRate":-0.0015037593984961195,"floatShares":141800000,"shares":141800000,"eps":1.9042696294437733,"marketStatus":"Closed","change":-0.03,"latestTime":"09-10 16:08:42","open":19.6,"high":20,"low":19.5,"amount":1999621,"amplitude":0.025063,"askPrice":20,"askSize":3400,"bidPrice":19.92,"bidSize":1800,"shortable":0,"etf":0,"ttmEps":1.3913096266054037,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1789090200000},"marketStatusCode":5,"adr":0,"listingDate":1751212800000,"exchange":"SEHK","adjPreClose":19.95,"openAndCloseTimeList":[[1789003800000,1789012800000],[1789016400000,1789027200000]],"volumeRatio":1.043568,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"03880\",,,,,undefined,":{"symbol":"03880","floatShares":141800000,"roa":"6.82%","roe":"10.89%","lyrEps":1.90427,"volumeRatio":1.043568,"shares":141800000,"dividePrice":0,"high":20,"amplitude":0.025063,"preClose":19.95,"low":19.5,"week52Low":19,"pbRate":"1.48","psRate":"4.39","week52High":34.3,"institutionHeld":0,"latestPrice":19.92,"committee":-0.307692,"eps":1.9042696294437733,"divideRate":0,"volume":100600,"delay":0,"ttmEps":1.3913096266054037,"open":19.6,"prevYearClose":30.48,"prevWeekClose":21.38,"prevMonthClose":22.18,"prevQuarterClose":22.08,"fiveDayClose":21.1,"twentyDayClose":21.44,"sixtyDayClose":24.3},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/03880\",params:#limit:5,,,undefined,":[{"date":"2026-08-27","symbol":"03880","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787794200000,"name":null,"time":"","dateTimestamp":1787760000000,"actualEps":null},{"date":"2026-03-30","symbol":"03880","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1774834200000,"name":null,"time":"","dateTimestamp":1774800000000,"actualEps":null},{"date":"2025-08-29","symbol":"03880","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756431000000,"name":null,"time":"","dateTimestamp":1756396800000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"03880\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"03880\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0,"buy":0,"hold":1,"sell":0,"strongSell":0,"meanLabel":"HOLD","meanPercent":1,"analysts":1,"updateTime":1754409600000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/03880\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"03880","date":"2026-09-09","current":14.303523,"percent":0.342373,"low":11.049775,"twenty":12.637598,"median":31.026296,"eighty":37.833512,"high":89.502411,"avg":32.270008,"sd":21.37549,"marketCap":2828910000},"quantilePoints":[{"date":"2025-06-27","current":64.550519,"twenty":64.550519,"median":64.550519,"eighty":64.550519,"marketCap":4183100000},{"date":"2025-07-04","current":69.032987,"twenty":66.795355,"median":68.595377,"eighty":69.313609,"marketCap":4473790000},{"date":"2025-07-11","current":68.445519,"twenty":67.311524,"median":68.276633,"eighty":68.994281,"marketCap":4431250000},{"date":"2025-07-18","current":76.171108,"twenty":67.389311,"median":68.984604,"eighty":75.214843,"marketCap":4927550000},{"date":"2025-07-25","current":74.03868,"twenty":67.965697,"median":71.906475,"eighty":74.616858,"marketCap":4807020000},{"date":"2025-08-01","current":77.026259,"twenty":68.377965,"median":73.828208,"eighty":76.342138,"marketCap":4970090000},{"date":"2025-08-08","current":73.611635,"twenty":68.565405,"median":73.719922,"eighty":75.214843,"marketCap":4761644000},{"date":"2025-08-15","current":78.991101,"twenty":68.906759,"median":73.83709,"eighty":76.342138,"marketCap":5101964000},{"date":"2025-08-22","current":89.502411,"twenty":69.02331,"median":74.090002,"eighty":78.320217,"marketCap":5762752000},{"date":"2025-08-29","current":78.512395,"twenty":70.155476,"median":74.257083,"eighty":79.74991,"marketCap":5079276000},{"date":"2025-09-05","current":41.646228,"twenty":68.906759,"median":74.188856,"eighty":79.74991,"marketCap":5031064000},{"date":"2025-09-12","current":37.986037,"twenty":67.389311,"median":74.066692,"eighty":79.087699,"marketCap":4597156000},{"date":"2025-09-19","current":35.879032,"twenty":42.439428,"median":73.832649,"eighty":78.741923,"marketCap":4339080000},{"date":"2025-09-26","current":35.972365,"twenty":39.207677,"median":73.603619,"eighty":78.545842,"marketCap":4339080000},{"date":"2025-10-03","current":36.895298,"twenty":38.254613,"median":73.439791,"eighty":78.477782,"marketCap":4461028000},{"date":"2025-10-10","current":35.939087,"twenty":37.926552,"median":73.260895,"eighty":78.387462,"marketCap":4339080000},{"date":"2025-10-17","current":35.261849,"twenty":36.980504,"median":69.008796,"eighty":78.069934,"marketCap":4254000000},{"date":"2025-10-24","current":35.954012,"twenty":36.188249,"median":68.445519,"eighty":77.701013,"marketCap":4339080000},{"date":"2025-10-31","current":35.900465,"twenty":36.021695,"median":67.397498,"eighty":77.513348,"marketCap":4339080000},{"date":"2025-11-07","current":35.922904,"twenty":35.979492,"median":65.840942,"eighty":76.855229,"marketCap":4339080000},{"date":"2025-11-14","current":36.196001,"twenty":35.973277,"median":41.646228,"eighty":76.009632,"marketCap":4384456000},{"date":"2025-11-21","current":32.839875,"twenty":35.967307,"median":40.069862,"eighty":75.286139,"marketCap":3976072000},{"date":"2025-11-28","current":33.374508,"twenty":35.955467,"median":38.580928,"eighty":74.943808,"marketCap":4055480000},{"date":"2025-12-05","current":32.851251,"twenty":35.944759,"median":38.254067,"eighty":74.758171,"marketCap":3998760000},{"date":"2025-12-12","current":33.023157,"twenty":35.900465,"median":37.886895,"eighty":74.473119,"marketCap":4027120000},{"date":"2025-12-19","current":34.430381,"twenty":35.39442,"median":37.394857,"eighty":74.229792,"marketCap":4208624000},{"date":"2025-12-24","current":34.99421,"twenty":35.141853,"median":37.085683,"eighty":74.147921,"marketCap":4290868000},{"date":"2026-01-02","current":33.635992,"twenty":35.029056,"median":36.743987,"eighty":74.11624,"marketCap":4140560000},{"date":"2026-01-09","current":32.725127,"twenty":34.456149,"median":36.454304,"eighty":74.08534,"marketCap":4038464000},{"date":"2026-01-16","current":32.687847,"twenty":33.647972,"median":36.236629,"eighty":74.049885,"marketCap":4046972000},{"date":"2026-01-23","current":31.091299,"twenty":33.318703,"median":36.073206,"eighty":73.917726,"marketCap":3845616000},{"date":"2026-01-30","current":31.269354,"twenty":33.177249,"median":36.016394,"eighty":73.831761,"marketCap":3885320000},{"date":"2026-02-06","current":27.433753,"twenty":32.966335,"median":35.983345,"eighty":73.698264,"marketCap":3417380000},{"date":"2026-02-13","current":29.767101,"twenty":32.846701,"median":35.969241,"eighty":73.606825,"marketCap":3729340000},{"date":"2026-02-20","current":29.696692,"twenty":32.725127,"median":35.967659,"eighty":73.603619,"marketCap":3715160000},{"date":"2026-02-27","current":28.724265,"twenty":32.439619,"median":35.961022,"eighty":73.603001,"marketCap":3632916000},{"date":"2026-03-06","current":25.544273,"twenty":32.105235,"median":35.955322,"eighty":73.439791,"marketCap":3204680000},{"date":"2026-03-13","current":25.719686,"twenty":31.941403,"median":35.950844,"eighty":73.376851,"marketCap":3241548000},{"date":"2026-03-20","current":24.620311,"twenty":31.419436,"median":35.939087,"eighty":73.260895,"marketCap":3091240000},{"date":"2026-03-27","current":25.407751,"twenty":30.961293,"median":35.900465,"eighty":70.436098,"marketCap":3181992000},{"date":"2026-04-02","current":12.694395,"twenty":30.374151,"median":35.877946,"eighty":69.313609,"marketCap":3139452000},{"date":"2026-04-10","current":12.836208,"twenty":29.799581,"median":35.844414,"eighty":69.013634,"marketCap":3199008000},{"date":"2026-04-17","current":12.660198,"twenty":28.991894,"median":35.202659,"eighty":68.828913,"marketCap":3156468000},{"date":"2026-04-24","current":12.397874,"twenty":27.75939,"median":35.115214,"eighty":68.535434,"marketCap":3091240000},{"date":"2026-04-30","current":12.269611,"twenty":26.785787,"median":34.99421,"eighty":68.377965,"marketCap":3060044000},{"date":"2026-05-08","current":12.363155,"twenty":25.983648,"median":34.594549,"eighty":67.965697,"marketCap":3094076000},{"date":"2026-05-15","current":12.534163,"twenty":25.665008,"median":34.175169,"eighty":67.389311,"marketCap":3145124000},{"date":"2026-05-22","current":12.642172,"twenty":25.399381,"median":33.645975,"eighty":67.311524,"marketCap":3164976000},{"date":"2026-05-29","current":12.270986,"twenty":25.218458,"median":33.406025,"eighty":67.131365,"marketCap":3082732000},{"date":"2026-06-05","current":11.125953,"twenty":24.642571,"median":33.30501,"eighty":64.550519,"marketCap":2799132000},{"date":"2026-06-12","current":13.017265,"twenty":13.007169,"median":33.187074,"eighty":42.637728,"marketCap":3272744000},{"date":"2026-06-18","current":12.671021,"twenty":12.943368,"median":33.126975,"eighty":41.844528,"marketCap":3193336000},{"date":"2026-06-26","current":12.518344,"twenty":12.901138,"median":33.023157,"eighty":41.133711,"marketCap":3139452000},{"date":"2026-07-03","current":12.429887,"twenty":12.724861,"median":32.858736,"eighty":40.911062,"marketCap":3119600000},{"date":"2026-07-10","current":13.463401,"twenty":12.685266,"median":32.845563,"eighty":39.914225,"marketCap":3374840000},{"date":"2026-07-17","current":13.021079,"twenty":12.724861,"median":32.687847,"eighty":39.039678,"marketCap":3275580000},{"date":"2026-07-24","current":12.950528,"twenty":12.774507,"median":32.49883,"eighty":38.697228,"marketCap":3258564000},{"date":"2026-07-31","current":12.667228,"twenty":12.718655,"median":32.350921,"eighty":38.507791,"marketCap":3193336000},{"date":"2026-08-07","current":11.576024,"twenty":12.668745,"median":32.105235,"eighty":38.341571,"marketCap":2923916000},{"date":"2026-08-14","current":12.133289,"twenty":12.639428,"median":31.958711,"eighty":38.254613,"marketCap":3068552000},{"date":"2026-08-21","current":13.057601,"twenty":12.633554,"median":31.917498,"eighty":38.145216,"marketCap":3309612000},{"date":"2026-08-28","current":15.462922,"twenty":12.621641,"median":31.567575,"eighty":37.94638,"marketCap":3048700000},{"date":"2026-09-04","current":15.370447,"twenty":12.633554,"median":31.132408,"eighty":37.865542,"marketCap":3031684000},{"date":"2026-09-09","current":14.319477,"twenty":12.637598,"median":31.026296,"eighty":37.833512,"marketCap":2828910000}],"updateTime":1789031221526},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"03880\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2665322134","title":"Precision Peptide Starts U.S. Testing of Thymosin Alpha-1 Transdermal Patch","url":"https://stock-news.laohu8.com/highlight/detail?id=2665322134","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665322134?lang=en_us&edition=fundamental","pubTime":"2026-09-08 19:04","pubTimestamp":1788865487,"startTime":"0","endTime":"0","summary":"Precision Peptide starts U.S. testing of Thymosin Alpha-1 transdermal patchThe Precision Peptide Company started formal U.S. testing of a Thymosin Alpha-1 transdermal patch, targeting completion in Q3","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nNDLc8w6w6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1141","03880"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662095636","title":"Medtide (SEHK:3880) Stock Drifts As Margin Gains Meet Revenue Reset","url":"https://stock-news.laohu8.com/highlight/detail?id=2662095636","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662095636?lang=en_us&edition=fundamental","pubTime":"2026-08-28 19:33","pubTimestamp":1787916832,"startTime":"0","endTime":"0","summary":"Medtide shares have drifted lower over the past week and month, yet the latest half year earnings land with a very different message. The headline is margin power. Net profit margin over the last 12 months is 30.7%, compared with 22.2% a year earlier, while earnings per share on that same basis sit at 1.19 CNY. The stock closed at HK$21.5 on a trailing P/E of 15.5x, which leaves today’s muted price reaction at odds with the profitability story Medtide just put on the table.\nLove Medtide’s...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-3880/medtide-shares/news/medtide-sehk3880-stock-drifts-as-margin-gains-meet-revenue-r","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-3880/medtide-shares/news/medtide-sehk3880-stock-drifts-as-margin-gains-meet-revenue-r","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["PMDE","VGFPF","GXDW","03880","DECU","FEBU","BK1141","RGLO","VOTE","JOYT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158944843","title":"MEDTIDE Proposes Adoption of Restricted Share Unit Scheme","url":"https://stock-news.laohu8.com/highlight/detail?id=1158944843","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1158944843?lang=en_us&edition=fundamental","pubTime":"2026-08-27 16:52","pubTimestamp":1787820762,"startTime":"0","endTime":"0","summary":"MEDTIDE (03880) announced that on August 27, 2026, its board of directors passed resolutions concerning the proposed adoption of a restricted share unit scheme and the proposed adoption of a service...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1141","03880"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128983823","title":"MEDTIDE Posts 47.4% Drop in Net Profit for Interim Results","url":"https://stock-news.laohu8.com/highlight/detail?id=1128983823","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1128983823?lang=en_us&edition=fundamental","pubTime":"2026-08-27 16:41","pubTimestamp":1787820096,"startTime":"0","endTime":"0","summary":"MEDTIDE (03880) has released its interim results for 2026, reporting revenue of approximately RMB 235 million, a year-on-year decrease of 7.6%. Gross profit stood at around RMB 136 million, down...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1141","03880"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662774375","title":"Medtide Proposes Bylaw Changes to Allow Board Size Range of Five to Nine Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2662774375","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662774375?lang=en_us&edition=fundamental","pubTime":"2026-08-27 16:40","pubTimestamp":1787820000,"startTime":"0","endTime":"0","summary":"Medtide proposes bylaw changes to allow board size range of five to nine directorsMedtide unveiled bylaw changes covering its Articles of Association plus board and shareholder-meeting procedure rules","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nNDL2FjHyP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03880","BK1141"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662748347","title":"Medtide Proposes 10-Year RSU Incentive Scheme with 14,180,000-Share Mandate Limit","url":"https://stock-news.laohu8.com/highlight/detail?id=2662748347","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662748347?lang=en_us&edition=fundamental","pubTime":"2026-08-27 16:35","pubTimestamp":1787819708,"startTime":"0","endTime":"0","summary":"Medtide proposes 10-year RSU incentive scheme with 14,180,000-share mandate limitMedtide set plans to adopt a 2026 RSU Scheme, subject to shareholder approval at an extraordinary general meeting.Schem","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nNDL5TZL4k:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1141","03880"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662747771","title":"Medtide Hy Revenue Rmb234.5 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2662747771","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662747771?lang=en_us&edition=fundamental","pubTime":"2026-08-27 16:32","pubTimestamp":1787819534,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nPLXL0Q8SQ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["03880","BK1141"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662771718","title":"Medtide H1 FY26 Profit Drops 47.4% to RMB 53.68 Million; Revenue Falls 7.6% to RMB 234.52 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2662771718","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662771718?lang=en_us&edition=fundamental","pubTime":"2026-08-27 16:31","pubTimestamp":1787819477,"startTime":"0","endTime":"0","summary":"Medtide H1 FY26 profit drops 47.4% to RMB 53.68 million; revenue falls 7.6% to RMB 234.52 millionMedtide posted IFRS profit attributable to owners of the parent of RMB 53.68 million, down 47.4% year o","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nNDL2y4PHw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1141","03880"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660473224","title":"Precision Peptide Develops Needle-Free Tirzepatide Transdermal Patch in U.S","url":"https://stock-news.laohu8.com/highlight/detail?id=2660473224","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660473224?lang=en_us&edition=fundamental","pubTime":"2026-08-19 19:04","pubTimestamp":1787137449,"startTime":"0","endTime":"0","summary":"Precision Peptide develops needle-free tirzepatide transdermal patch in U.SThe Precision Peptide Company is developing a needle-free tirzepatide transdermal patch in the U.S. as an expansion of its de","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260819:nNDL4zwmm5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03880","BK1141"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660124483","title":"Medtide Schedules Board Meeting to Review Interim Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2660124483","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660124483?lang=en_us&edition=fundamental","pubTime":"2026-08-17 16:34","pubTimestamp":1786955640,"startTime":"0","endTime":"0","summary":"Medtide schedules board meeting to review interim resultsMedtide will hold a board meeting on Aug. 27, 2026 to consider interim results for the six months ended June 30, 2026.Disclaimer:This news brie","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260817:nNDL6Gc7j2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1141","03880"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119829447","title":"Hong Kong Stock CXO Sector Rallies; Will MEDTIDE (03880) Defy the Trend or Bounce Back After Its Profit Warning?","url":"https://stock-news.laohu8.com/highlight/detail?id=1119829447","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1119829447?lang=en_us&edition=fundamental","pubTime":"2026-08-07 10:26","pubTimestamp":1786069600,"startTime":"0","endTime":"0","summary":" On July 31, after the market close, MEDTIDE (03880) issued a profit warning for its 26H1 fiscal year. The company expects period revenue of approximately RMB 229.8-239.2 million, a year-over-year...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","VXUS","CXO","03880","BK1141","NIFE","WX","KCAI","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657544565","title":"Cpc Scientific Announces U.S. FDA Pre-License Inspection (Pli) Successfully Completed at Its Hangzhou Cgmp Manufacturing Facility for Hepcludex® API, Establishing a Proven Track Record Under the Stringent Bla Pathway","url":"https://stock-news.laohu8.com/highlight/detail?id=2657544565","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657544565?lang=en_us&edition=fundamental","pubTime":"2026-08-05 20:11","pubTimestamp":1785931860,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nTUA7VZCWP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1141","03880"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150516282","title":"Medtide Posts Steady July 2026 Share Capital; Public Float Remains Compliant","url":"https://stock-news.laohu8.com/highlight/detail?id=1150516282","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1150516282?lang=en_us&edition=fundamental","pubTime":"2026-08-05 17:29","pubTimestamp":1785922152,"startTime":"0","endTime":"0","summary":"Medtide Inc. filed its Monthly Return for Equity Issuer for the period ended 31 July 2026, confirming that the company’s share structure remained unchanged throughout the month. • Authorised/Issued...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03880"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148679402","title":"Medtide completes U.S. FDA Pre-License Inspection for Hepcludex API at Hangzhou facility","url":"https://stock-news.laohu8.com/highlight/detail?id=1148679402","media":"Bulletin Express","labels":["policyRegulatory","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1148679402?lang=en_us&edition=fundamental","pubTime":"2026-07-31 16:47","pubTimestamp":1785487636,"startTime":"0","endTime":"0","summary":"Medtide Inc. (MEDTIDE) announced that its wholly owned subsidiary Chinese Peptide Company has passed a U.S. Food and Drug Administration Pre-License Inspection (PLI) for the commercial production of...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03880"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120383613","title":"MEDTIDE (03880) Issues Profit Warning, Expects First-Half Profit to Drop Approximately 44% to 51.6% Year-on-Year","url":"https://stock-news.laohu8.com/highlight/detail?id=1120383613","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1120383613?lang=en_us&edition=fundamental","pubTime":"2026-07-31 16:44","pubTimestamp":1785487468,"startTime":"0","endTime":"0","summary":"MEDTIDE (03880) has issued an announcement regarding its financial performance for the six months ending June 30, 2026, compared to the same period in 2025. The board anticipates that revenue will...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1141","03880"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107085569","title":"MEDTIDE's HEPCLUDEX® Active Ingredient Passes FDA Pre-License Inspection","url":"https://stock-news.laohu8.com/highlight/detail?id=1107085569","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1107085569?lang=en_us&edition=fundamental","pubTime":"2026-07-31 16:44","pubTimestamp":1785487449,"startTime":"0","endTime":"0","summary":"MEDTIDE (03880) has announced that its wholly-owned subsidiary, Zhongtai Shenghua Co., Ltd. (\"Zhongtai Shenghua\"), has successfully completed a Pre-License Inspection (PLI) by the U.S. Food and Drug...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","IPOS","LABU","03880","BK1141","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112713365","title":"MEDTIDE Appoints New CFO and Revamps Key Management Positions","url":"https://stock-news.laohu8.com/highlight/detail?id=1112713365","media":"Stock News","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1112713365?lang=en_us&edition=fundamental","pubTime":"2026-07-31 16:38","pubTimestamp":1785487097,"startTime":"0","endTime":"0","summary":"MEDTIDE (03880) has announced a series of key management changes, effective from July 31, 2026. Ms. Ding Lijun has been appointed as the Chief Financial Officer, where she will oversee the group's...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03880","BK1141"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655356459","title":"Medtide Unit Chinese Peptide Completes US FDA Pre-license Inspection for Hepcludex API Facility","url":"https://stock-news.laohu8.com/highlight/detail?id=2655356459","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655356459?lang=en_us&edition=fundamental","pubTime":"2026-07-31 16:35","pubTimestamp":1785486919,"startTime":"0","endTime":"0","summary":"Medtide unit Chinese Peptide completes US FDA pre-license inspection for Hepcludex API facilityChinese Peptide, a wholly owned Medtide subsidiary, cleared a US FDA pre-license inspection for Hepcludex","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260731:nNDL8fHx2L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03880","BK1141"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655356455","title":"Medtide Names Ding Lijun as CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2655356455","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655356455?lang=en_us&edition=fundamental","pubTime":"2026-07-31 16:35","pubTimestamp":1785486901,"startTime":"0","endTime":"0","summary":"Medtide names Ding Lijun as CFONamed Ding Lijun as chief financial officer effective July 31, 2026; she was CFO of Inventronics (Hangzhou) from Feb 2025 to Jul 2026.Ding previously served as finance v","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260731:nNDL6fMHMp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2097828631.EUR","03880","LU2097828714.EUR","LU2097828805.USD","LU2242644610.SGD","LU0455707207.USD","HK0000165453.HKD","BK0214","BK1589","LU1969619763.USD","01801","300582","LU0502904849.HKD","LU2328871848.SGD","LU2488822045.USD","BK1141","KURE","LU2097828474.EUR","LU2097828557.USD","BK1161","BK1583","BK0247","300577"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655356956","title":"Medtide - Subsidiary Completes U.S. FDA Pre-License Inspection at Hangzhou Facility","url":"https://stock-news.laohu8.com/highlight/detail?id=2655356956","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655356956?lang=en_us&edition=fundamental","pubTime":"2026-07-31 16:33","pubTimestamp":1785486838,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260731:nFWN43X0T9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1141","03880"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":54,"code":"91000000","status":"200"}]}}